AMAG PHARMACEUTICALS,INC. (NASDAQ:AMAG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 29, 2017, AMAG Pharmaceuticals, Inc. (the “Company”), in connection with its annual compensation review and upon the advice of its outside compensation consultant, and William K. Heiden, the Company’s President and Chief Executive Officer, entered into an amendment of Mr. Heiden's employment agreement (the “Amendment”) in order to make the excise tax-related provision of Mr. Heiden's employment agreement consistent with the Company's other existing executive employment agreements. The amended provision provides that any payments and benefits due to Mr. Heiden in connection with a change of control that would otherwise be subject to an excise tax under Section 4999 of the Internal Revenue Code shall be reduced, but only if such reduction would result in Mr. Heiden retaining a larger portion of such payments on an after-tax basis than if no reduction was made and the excise taxes had been paid (a so-called modified cutback provision). The outline of the Amendment terms described herein does not purport to be a complete description of the Amendment and is qualified in its entirety by the copy of the Amendment filed as Exhibit 10.1 to this report and incorporated by reference hereto. The other terms of Mr. Heiden’s employment agreement are described in the Company’s definitive proxy statement, beginning on page 50, filed with the U.S. Securities and Exchange Commission on April 20, 2017 and the employment agreement is filed as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014, which description and exhibit are incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
The Company hereby files the following exhibits:
AMAG PHARMACEUTICALS INC. ExhibitEX-10.1 2 ex101.htm EXHIBIT 10.1 Exhibit AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENTThis Amendment to Amended and Restated Employment Agreement (the “Amendment”) is entered into as of November 29,…To view the full exhibit click
About AMAG PHARMACEUTICALS,INC. (NASDAQ:AMAG)
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.